Published in Curr Pharm Des on January 01, 2004
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
High-performance liquid chromatography-mass spectrometry for mapping and sequencing glycosaminoglycan-derived oligosaccharides. Nat Protoc (2010) 1.07
Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS One (2011) 1.01
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev (2009) 0.94
Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J (2006) 0.93
Sugar-coating wound repair: a review of FGF-10 and dermatan sulfate in wound healing and their potential application in burn wounds. J Burn Care Res (2012) 0.86
The "CPC clip motif": a conserved structural signature for heparin-binding proteins. PLoS One (2012) 0.86
Targeted glycomics by selected reaction monitoring for highly sensitive glycan compositional analysis. Proteomics (2012) 0.79
GS-align for glycan structure alignment and similarity measurement. Bioinformatics (2015) 0.78
Microarray method for the rapid detection of glycosaminoglycan-protein interactions. Methods Mol Biol (2012) 0.77
Dermatan sulfate in tunicate phylogeny: order-specific sulfation pattern and the effect of [→4IdoA(2-sulfate)β-1→3GalNAc(4-sulfate)β-1→] motifs in dermatan sulfate on heparin cofactor II activity. BMC Biochem (2011) 0.77
Analysis of Glycosaminoglycans Using Mass Spectrometry. Curr Proteomics (2015) 0.76
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem (2005) 2.03
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem (2005) 1.27
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol (2010) 1.21
P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J (2007) 1.14
Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem (2005) 1.09
Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost (2007) 1.08
Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost (2009) 1.06
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia (2011) 0.99
Dynamic properties of biologically active synthetic heparin-like hexasaccharides. Glycobiology (2005) 0.98
Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy. Biochemistry (2008) 0.98
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. J Med Chem (2010) 0.96
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction. J Am Coll Cardiol (2013) 0.96
Heparanase, heparin and the coagulation system in cancer progression. Thromb Res (2007) 0.95
Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromolecules (2005) 0.95
Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J (2006) 0.93
Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org Biomol Chem (2010) 0.92
An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence. Biochem J (2013) 0.91
Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives. Glycobiology (2007) 0.91
Surface functionalization of cotton cellulose with glycidyl methacrylate and its application for the adsorption of aromatic pollutants from wastewaters. J Hazard Mater (2009) 0.90
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. Thromb Res (2011) 0.89
Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology (2010) 0.87
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology (2004) 0.87
Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans. Semin Thromb Hemost (2002) 0.86
Glycosaminoglycan origin and structure revealed by multivariate analysis of NMR and CD spectra. Glycobiology (2008) 0.85
A novel computational approach to integrate NMR spectroscopy and capillary electrophoresis for structure assignment of heparin and heparan sulfate oligosaccharides. Glycobiology (2002) 0.85
Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides. Anal Biochem (2012) 0.85
Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1. Biochem Biophys Res Commun (2002) 0.84
Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-beta-D-glucosamine or N-sulfated 1,6-anhydro-beta-D-mannosamine residues. Carbohydr Res (2006) 0.84
Interaction of heparins with fibroblast growth factors: conformational aspects. Curr Pharm Des (2007) 0.83
Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis. Anal Chem (2012) 0.82
Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution. Semin Thromb Hemost (2002) 0.82
The tainted heparin story: an update. Thromb Haemost (2009) 0.82
Low-molecular-weight heparin from Cu2+ and Fe2+ Fenton type depolymerisation processes. Thromb Haemost (2010) 0.81
Unravelling structural information from complex mixtures utilizing correlation spectroscopy applied to HSQC spectra. Anal Chem (2013) 0.81
A robust method to quantify low molecular weight contaminants in heparin: detection of tris(2-n-butoxyethyl) phosphate. Analyst (2011) 0.81
Anti-metastatic semi-synthetic sulfated maltotriose C-C linked dimers. Synthesis and characterisation. Molecules (2012) 0.80
High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin Thromb Hemost (2007) 0.80
Insights into the human glycan receptor conformation of 1918 pandemic hemagglutinin-glycan complexes derived from nuclear magnetic resonance and molecular dynamics studies. Biochemistry (2014) 0.79
Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human Cathepsin G. Biochem Pharmacol (2005) 0.79
Cycloartane and oleanane saponins from egyptian astragalus spp. as modulators of lymphocyte proliferation. Planta Med (2002) 0.79
Heparin dodecasaccharide containing two antithrombin-binding pentasaccharides: structural features and biological properties. J Biol Chem (2013) 0.79
Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments. Anal Bioanal Chem (2013) 0.78
Cations modulate polysaccharide structure to determine FGF-FGFR signaling: a comparison of signaling and inhibitory polysaccharide interactions with FGF-1 in solution. Biochemistry (2009) 0.78
Structural modification induced in heparin by a Fenton-type depolymerization process. Semin Thromb Hemost (2007) 0.78
Antithrombin-binding oligosaccharides: structural diversities in a unique function? Glycoconj J (2014) 0.78
Non-covalent synthesis of metal oxide nanoparticle-heparin hybrid systems: a new approach to bioactive nanoparticles. Int J Mol Sci (2013) 0.78
O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost (2007) 0.78
Following protein-glycosaminoglycan polysaccharide interactions with differential scanning fluorimetry. Methods Mol Biol (2012) 0.77
Heparin-like heparan sulfate from rabbit cartilage. Glycobiology (2011) 0.77
Unusual partially 3-O-methylated alpha-galactan from mushrooms of the genus Pleurotus. Phytochemistry (2007) 0.77
Reversed-phase ion-pair ultra-high-performance-liquid chromatography-mass spectrometry for fingerprinting low-molecular-weight heparins. J Chromatogr A (2013) 0.77
Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns. Semin Thromb Hemost (2003) 0.76
Human milk oligosaccharides: an enzymatic protection step simplifies the synthesis of 3'- and 6'-O-sialyllactose and their analogues. Carbohydr Res (2002) 0.76
Focusing of low-molecular-mass heparins in polycationic polyacrylamide matrices. Anal Chem (2009) 0.75
Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations. Glycobiology (2011) 0.75
High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of 1H NMR spectra. Analyst (2011) 0.75
Radical-based grafting of GMA on sutures of different nature. Org Biomol Chem (2011) 0.75
Construction and use of a library of bona fide heparins employing 1H NMR and multivariate analysis. Analyst (2011) 0.75
Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative. Semin Thromb Hemost (2002) 0.75
Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins. Semin Thromb Hemost (2002) 0.75
A zinc complex of heparan sulfate destabilises lysozyme and alters its conformation. Biochem Biophys Res Commun (2012) 0.75
Structure of a heteroxylan of gum exudate of the palm Scheelea phalerata (uricuri). Phytochemistry (2004) 0.75
How to find a needle (or anything else) in a haystack: two-dimensional correlation spectroscopy-filtering with iterative random sampling applied to pharmaceutical heparin. Anal Chem (2012) 0.75